Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma

British Journal of Cancer

Volumn 77, Issue 4, 1998, Pages 627-631

  Wood, L ^a   Palmer, M ^a   Hewitt, J ^a   Urtasun, R ^a   Bruera, E ^a   Rapp, E ^b   Thaell, J F ^c  

^a CROSS CANCER INSTITUTE   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

^c Calgary General Hospital   (Canada)

Author keywords

Drug resistance; Megestrol acetate; P glycoprotein; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MEGESTROL ACETATE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESISTANCE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT OUTCOME;

EID: 0031963639     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.100     Document Type: Article

References (28)

1. Arvelo F, Le Chevalier T, Arriagada R, Jacrot M, Brambilla C and Poupon MF (1990) Post chemotherapy relapse in small cell lung carcinoma correlates with overexpression of growth-related genes, and multidrug-resistance (abstract A2196). Proc AACR 31: 370
2. Bellamy WT and Dalton WS (1994) Multidrug resistance in the laboratory and clinic. Adv Clin Chem 31: 10-61
3. Bellamy WT, Dalton WS, Kailey JM, Gleason MC, McCloskey TM, Dorr RT and Alberts DS (1988) Verapamil reversal of doxorubicin resistance in multidrug-resistance human myeloma cells and association with drug accumulation and DNA damage. Cancer Res 48: 6303-6308
4. Bruera E, Macmillan K, Kuehn N, Hanson J and Macdonald RN (1990) A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 66: 1279-1282
5. Chin KV, Pastan I and Gottesman MM (1993) Function and regulation of the human multidrug resistance gene. Adv Cancer Res 60: 157-180
6. Cole SPC, Downes HF and Slovak ML (1989) Effect of calcium antagonists on the chemosensitivity of two multidrug resistant human tumor cells lines which do not overexpress P-glycoprotein. Br J Cancer 59: 42-46
7. Cole SPC, Bhardwaj G, Gerlach JF, Mackie JG, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG (1992) Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 258: 1650-1654
8. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR and Melamed MR (1990) Expression of the multidrug resistance gene product (p-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287
9. Dalton WS, Crowley JJ, Salmon SS, Groggan TM, Laufman LR, Weiss GR and Bonnet JD (1995) A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with retractory myeloma. Cancer 75: 815-820
10. De Jong S, Zijlstra JG, De Vries EGE and Mulder NH (1990) Reduced DNA topoisomerase II activity in drug-induced DNA cleavage activity in adriamycin resistant human small cell lung cancer cell line. Cancer Res 50: 304-309
11. Fleming GF, Amato JM, Agresti M and Safa AR (1992) Megestrol acetate reverses multidrug resistance and interacts with p-glycoprotein. Cancer Chemother Pharmacol 29: 445-449
12. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM and Pastan I (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265-269
13. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM and Pastan I (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124
14. Gottesman MM and Pastan I (1988) The multidrug transporter, a double-edged sword. J Biol Chem 263: 12163-12166
15. Hopwood P, Stephens RJ and Machin D (1994) Approaches to the analysis of quality of life data: experiences gained from the Medical Research Council Lung Cancer Working Party palliative chemotherapy trial. Qual Life Res 3: 339-352
16. Ihde DC, Pass HI and Glatstein EJ (1993) Cancer of the lung. In Cancer: Principles and Practice of Oncology (4th edn), Devita VT, Hellman S and Rosenberg SA, (eds), pp. 723-758, Lippincott: Philadelphia
17. Lai SL, Goldstein LJ, Gottesman MM, Pastan I, Tsai C, Johnson BE, Mulshine JL, Ihde DC, Kayser K and Gazdor AF (1989) MDR1 gene expression in lung cancer. J Natl Cancer Inst 81: 1144-1150
18. Loprinizi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM, Mailliard JA, Johnson PS, Ebbert LP and Seeraerts LH (1990) Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 82: 1127-1132
19. Millward MJ, Cantwell BMJ, Nunro NC, Robinson A, Corris PA and Harris AL (1993) Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer 67: 1031-1035
20. Milroy R (1993) A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. Br J Cancer 68: 813-818
21. Minato K, Kanzawa F, Nishio K, Nakagawa K, Fujiwara Y and Saijo N (1990) Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother Pharmacol 26: 313-317
22. Mirski SEL, Gerlach HF and Cole SPC (1987) Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 47: 2594-2598
23. Reeve JG, Rabbitts PH and Twentyman PR (1989) Amplification and expression of mdrl gene in a multidrug resistant variant of small cell lung cancer cell line NCI-H69. Br J Cancer 60: 339-342
24. Rowland KM, Loprinzi CL, Shaw EG, Maksymiuk AW, Kuross SA, Jung S, Kugler JW, Tschetter LK, Ghosh C, Schaefer PL, Owen D, Washburn JH, Webb TA, Mailliard JA and Jett JR (1996) Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 14: 135-141
25. Tchekmedyian S, Tait N, Moody M and Aisner J (1987) High-dose megestrol acetate, a possible treatment for cachexia. JAMA 9: 1195-1198
26. Twentyman PR, Fox NE and White DJG (1987) Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multidrug resistance human lung cancer cell line. Br J Cancer 56: 55-57
27. Wang L, Yang CPH, Trail P, Horwitz SB and Casazza AM (1991) Reversal of the multidrug resistance phenotype with megestrol acetate (abstract 2239). Proc AACR 32: 377
28. Wishart GC, Bissett D, Paul J, Jodrell D, Harnett A, Habeshaw, T, Kerr DJ, Macham MA, Soukop M, Leonard RCF, Knepil J and Kaye SB (1994) Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol 12: 1771-1777